Company: BNBX
Filing Date: 2025-11-04
Form Type: 424B5
Source: 0001104659-25-105958
Chunk: 29

Company: BNB PLUS CORP.
Filing Date: 2025-11-04
Form: 424B5
Chunk 29
---
 Agent Warrants, or Consultant Warrants are utilized.

On May 29, 2024, we closed on such date
a public offering whereupon we issued and sold units consisting of common stock purchase warrants to purchase one share of our common
stock (the “Series A Warrants”), which may be exercised through cashless exercise if, at the time of exercise, there
is no effective registration statement registering, or the prospectus contained therein is not available for, the resale of the shares
of common stock underlying the Series A Warrants by the holder thereof. If the Series A Warrants are exercised by way of a cashless exercise,
such exercising holder will receive shares of our common stock for each Series A Warrant.

Pursuant to the closing of the Private Placement,
the Series E Warrants, Advisory Warrants, and Consultant Warrants were issued. Additionally, in connection with the Private Placement,
the Company sold to Lucid warrants (the “Placement Agent Warrants”) to purchase shares of our common stock equal to 5.0% of
our common stock sold in the Private Placement at a price of $50. If the Series E Warrants, Advisory Warrants, Placement Agent Warrants,
or Consultant Warrants are exercised by way of a cashless exercise, which may occur six months after their issuance if no applicable registration
statement is available for the resale of such common stock, such exercising holder will receive shares of our common stock for each Series E
Warrant, Advisory Warrant, Placement Agent Warrant, or Consultant Warrant they exercise without any cash payment to us.

The number of shares of our common stock each
of the holders of the Series A Warrants, Series E Warrants, Advisory Warrants, Placement Agent Warrants, or Consultant Warrants are
entitled to receive upon a cashless exercise is subject to a formula as set forth in the relevant warrant.

If any of the above provisions in the Series A
Warrants, Series E Warrants, Advisory Warrants, Placement Agent Warrants or Consultant Warrants are utilized, our stockholders may
suffer substantial dilution.

| S-17 |

The common stock offered hereby will be sold in “at the market offerings” and investors who buy shares at different times will likely pay different prices.

Investors who purchase shares in this offering
at different times will likely pay different prices, and accordingly may experience different levels of dilution and different outcomes
in their investment results. We will have discretion, subject to market demand,